⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10538888 | 1.00 | — | — | |
| SCHEMBL9751039 | 0.76 | — | — | |
| SCHEMBL7997189 | 0.76 | — | — | |
| SCHEMBL9750872 | 0.76 | — | — | |
| SCHEMBL7999098 | 0.76 | — | — | |
| SCHEMBL6906897 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL10975038 | 0.67 | — | — | |
| SCHEMBL7506865 | 0.65 | — | — | |
| SCHEMBL5858529 | 0.65 | LMNA (0.34) | — | |
| SCHEMBL5858532 | 0.65 | LMNA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017107907-A1 | CONDENSED RING Γ-AMINO ACID DERIVATIVE AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2017-06-29 | — | — | WO | disclosed |
| CN-105784878-A | Method for analyzing and separating cis-bicyclo[3,2,0]hept-2-ene-6-one enantiomer by HPLC (High Performance Liquid Chromatography) | 长春百纯和成医药科技有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105784878-A | Method for analyzing and separating cis-bicyclo[3,2,0]hept-2-ene-6-one enantiomer by HPLC (High Performance Liquid Chromatography) | 长春百纯和成医药科技有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
| EP-1379494-B1 | FUSED BICYCLIC OR TRICYCLIC AMINO ACIDS | WARNER LAMBERT CO (US) | 2010-03-10 | — | — | EP | disclosed |
| WO-2004016260-A1 | THERAPEUTIC USE OF FUSED BICYCLIC OR TRICYCLIC AMINO ACIDS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |